VBIV - VBIワクチン (VBI Vaccines Inc.)

VBIVのニュース

   VBI Vaccines GAAP EPS of -$3.22, revenue of $0.49M  2023/05/15 13:23:24 Seeking Alpha
VBI Vaccines press release (VBIV): Q1 GAAP EPS of -$3.22.Revenue of $0.49M (+276.9% Y/Y).
   VBI Vaccines Reports First Quarter 2023 Financial Results  2023/05/15 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023. Jeff Baxter, VBI’s President and CEO, commented: “As highlighted earlier this year, we continue to focus on three core priorities: (1) making a difference in the fight against hepatitis B including prevention
   Raymond James maintains VBI Vaccines at Outperform  2023/04/13 14:01:37 Investing.com
https://www.investing.com/news/pro/paulson-capital-receives-investment-bank-analyst-rating-update-3054848
   VBI Vaccines Announces Cost Cutting Measures, Reverse Stock Split  2023/04/04 15:55:08 Benzinga
VBI Vaccines Inc (NASDAQ: VBIV ) plans to focus concentrating on broadening access to VBI''s FDA-approved 3-antigen HBV vaccine for adults, PreHevbrio [Hepatitis B Vaccine (Recombinant)], and advancing its HBV immunotherapeutic candidate, VBI-2601. The company will reduce its internal workforce by 30-35% – a reduction expected to begin in April and be complete by the end of June 2023. VBI also expects its operating expenses from normal … Full story available on Benzinga.com
   VBI Vaccines stock falls on portfolio overhaul, reverse stock split  2023/04/04 13:52:16 Seeking Alpha
VBI Vaccines (VBIV) lost 40% on Tuesday after announcing a reverse stock split, staff reduction and plans to reorganize its portfolio. Read the full story here.
   How is VBIV’s stock performing after recent trades?  2023/01/03 18:16:00 US Post News
VBI Vaccines Inc. (VBIV)’s stock has witnessed a price hike of 4.83% from the previous close with its current price standing at $0.41. Its current price is -83.40% under its 52-week high of $2.47 and 13.89% more than its 52-week low of $0.36. Based on the past 30-day period, the stock price is -28.38% below […]
   Looking Into VBI Vaccines''s Return On Capital Employed  2022/12/20 14:49:13 Benzinga
According to data from Benzinga Pro, during Q3, VBI Vaccines ''s (NASDAQ: VBIV ) reported sales totaled $317 thousand. Despite a 44.84% increase in earnings, the company posted a loss of $25.21 million. VBI Vaccines collected $346 thousand in revenue during Q2, but reported earnings showed a $45.70 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
   VBI Vaccines wins Health Canada approval for hepatitis B vaccine PreHevbrio (NASDAQ:VBIV)  2022/12/08 14:11:41 Seeking Alpha
Health Canada has approved VBI Vaccines (VBIV) hepatitis B vaccine PreHevbrio.The approval is the fourth for the triple-antigen shot.
   VBI Vaccines Inc.: CEPI Boosts ''Coronavirus X'' Vaccine Search With Expanded VBI Vaccines Deal  2022/12/06 14:27:00 Finanz Nachrichten
CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Prepared…
   CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal  2022/12/06 14:25:22 Financial Post
CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus OSLO, Norway & CAMBRIDGE, Mass. — The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) […]
   VBI Vaccines wins European recommendation for Hep B vaccine  2022/02/25 14:26:19 Seeking Alpha
VBI Vaccines (VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency ((EMA)) issued…
   VBIV stock gains after CDC nod for Hep B vaccine (NASDAQ:VBIV)  2022/02/23 21:22:10 Seeking Alpha
Cambridge, Massachusetts-based vaccine maker VBI Vaccines (VBIV) announced on Wednesday that an expert panel of the U.S
   VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022  2022/02/18 15:30:00 Marketing Sentinel
During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.85 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -5.88% or -$0.09. The 52-week high for the VBIV share is $4.31, that puts it down … VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »
   VBI Vaccines Inc. Shares Close in on 52-Week Low - Market Mover  2022/01/09 04:34:29 Kwhen Finance
VBI Vaccines Inc. (VBIV) shares closed today at 1.4% above its 52 week low of $2.09, giving the company a market cap of $545M. The stock is currently down 9.4% year-to-date, down 34.2% over the past 12 months, and down 37.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 31.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -24.7% The company's stock price performance over the past 12 months beats the peer average by -15.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   At 12.6% CAGR, Global Vaccines Market Size to Hit USD 153.49 Bn in 2028, Says Brandessence Market Research  2022/01/03 11:10:00 Kwhen Finance

calendar